Microbiology and Principles of Antimicrobial Therapy for Head and Neck Infections

Infectious Disease Clinics of North America

Volumn 21, Issue 2, 2007, Pages 355-391

  Brook, Itzhak ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFACLOR; CEFDINIR; CEFIXIME; CEFOXITIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; KETOLIDE; LEVOFLOXACIN; LORACARBEF; MACROLIDE; MONOBACTAM; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; SULFONAMIDE; TELITHROMYCIN; TRIMETHOPRIM; UNINDEXED DRUG;

ACUTE OTITIS MEDIA; ACUTE SINUSITIS; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL STRAIN; DRUG ACTIVITY; DRUG CHOICE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; GINGIVITIS; HAEMOPHILUS INFLUENZAE TYPE A; HEAD AND NECK INFECTION; HUMAN; LYMPHADENITIS; MASTOIDITIS; MORAXELLA CATARRHALIS; PERITONSILLAR ABSCESS; REVIEW; STREPTOCOCCUS PNEUMONIA; THYROIDITIS; TREATMENT DURATION; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; HEAD; HUMANS; NECK;

EID: 34249871928     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.03.014     Document Type: Review

References (106)

1. Finegold S.M. Anaerobic infections in humans: an overview. Anaerobe 1 (1995) 3-9
2. Brook I. The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection. Rev Infect Dis 6 (1984) 601-607
3. Butler J.C. Epidemiology of pneumococcal serotypes and conjugate vaccine formulations. Microb Drug Resist 3 (1997) 125-129
4. Joloba M.L., Windau A., Bajaksouzian S., et al. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media. Clin Infect Dis 33 (2001) 1489-1494
5. Nagai K., Davies T.A., Ednie L.M., et al. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob Agents Chemother 45 (2001) 3242-3245
6. Jacobs M.R., Felmingham D., Appelbaum P.C., et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 52 (2003) 229-246
7. Mera R.M., Miller L.A., Daniels J.J., et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis 51 (2005) 195-200
8. Fedler K.A., Biedenbach D.J., and Jones R.N. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 56 (2000) 427-436
9. Fasola E., Bajaksouzian S., Appelbaum P., et al. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae in four test methods. Antimicrob Agents Chemother 41 (1997) 129-134
10. Tait-Kamradt A., Davies T., Cronan M., et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 44 (2000) 2118-2125
11. Gill M.J., Brenwald N.P., and Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 43 (1999) 187-189
12. Felmingham D., and Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996. J Chemother 11 (1999) 5-21
13. Ubukata K., Shibasaki Y., Yamamoto K., et al. Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 45 (2001) 1693-1699
14. Jacobs M.R., Bajaksouzian S., Zilles A., et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother 43 (1999) 1901-1908
15. Peric M., Bozdogan B., Jacobs M.R., et al. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 47 (2003) 1017-1022
16. Brook I. Antibiotic resistance of oral anaerobic bacteria and their effect on the management of upper respiratory tract and head and neck infections. Semin Respir Infect 17 (2002) 195-203
17. Hecht D.W. Antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 12 (2006) 115-121
18. Lindbaek M. Acute sinusitis: guide to selection of antibacterial therapy. Drugs 64 (2004) 805-819
19. Brook I., Foote P.A., and Hausfeld J.N. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid. Int J Antimicrob Agents 26 (2005) 416-419
20. Brook I. The role of beta-lactamase producing bacteria and bacterial interference in streptococcal tonsillitis. Int J Antimicrob Agents 17 (2001) 439-442
21. Verklin R.M., and Mandell G.L. Alteration of antibiotics by anaerobiosis. J Lab Clin Med 89 (1977) 65-72
22. Craig W.A., and Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 15 (1996) 255-259
23. Vogelman B., Gudmundsson S., Leggett J., et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158 (1988) 831-847
24. Craig W. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
25. Maglio D., and Nicolau D.P. The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens. Methods Find Exp Clin Pharmacol 26 (2004) 781-788
26. Leach A., Shelby-James T., Mayo M., et al. A prospective study of the impact of community-based arithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 24 (1997) 356-362
27. Doern G.V. Macrolide and ketolide resistance with Streptococcus pneumoniae. Med Clin North Am 90 (2006) 1109-1124
28. Moore R.D., Lietman P.S., and Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 155 (1987) 93-99
29. Lister P.D., and Sanders C.C. Pharmacodynamics of moxifloxacin, levofloxacin, and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 47 (2001) 811-818
30. Forrest A., Nix D., and Ballow C. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
31. Lacy M.K., Lu W., Xu X., et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 43 (1999) 672-677
32. Stass H., and Dalhoff A. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints. Infection 33 Suppl 2 (2005) 29-35
33. Jacobs M.R., Bajaksouzian S., Windau A., et al. Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae. J Clin Microbiol 40 (2002) 2369-2376
34. Doern G.V. Activity of oral β-lactam antimicrobial agents versus respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the era of antibiotic resistance. Otolaryngol Head Neck Surg 127 (2002) S17-S23
35. Steele R.W., Thomas M.P., and Begue R.E. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 20 (2001) 1-5
36. Mattoes H.M., Kuti J.L., Drusano G.L., et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 26 (2004) 1187-1198
37. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother 48 (2004) 2464-2470
38. Dagan R., Leibovitz E., Fliss D.M., et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 44 (2000) 43-50
39. Doern G.V. Antimicrobial use and emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 33 Suppl 3 (2001) S187-S192
40. Christianson J, Andes DR, Craig WA. Pharmacodynamic characteristics of clindamycin against Streptococcus pneumoniae in a murine thigh-infection model [abstract A-1100]. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL), December 16-19, 2001.
41. Craig W.A. Does the dose matter?. Clin Infect Dis 33 Suppl 3 (2001) S233-S237
42. Ambrose P., and Owens R. New antibiotics in pulmonary critical care medicine; focus on advanced generation quinolones and cephalosporins. Semin Respir Crit Care Med 21 (2002) 19-32
43. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45 (2001) 1721-1729
44. Loesche W.J., Syed S.A., Laughon B.E., et al. The bacteriology of acute necrotizing ulcerative gingivitis. J Periodontol 53 (1982) 223-230
45. Socransky S.S., and Haffajee A.D. Evidence of bacterial etiology: a historical perspective. Periodontol 2000 5 (1994) 7-25
46. Shinn D.L. Vincent's disease and its treatment. In: Finegold S.M. (Ed). Metronidazole (1977), Bridgewater (NJ): Excerpta Medica 307-308
47. Brook I, Douma M. Antimicrobial therapy guide for the dentist. Newton (PA): Handbooks in Healthcare Co.; 2004.
48. Darby I., and Curtis M. Microbiology of periodontal disease in children and young adults. Periodontol 2000 26 (2001) 33-53
49. Loesche W.J. Rationale for the use of antimicrobial agents in periodontal disease. Int J Technol Assess Health Care 6 (1990) 403-417
50. Heimdahl A., Von-Konow L., and Nord C.E. Isolation of beta-lactamase producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections. Arch Oral Biol 25 (1980) 689-692
51. Loesche W.J., and Giordano J.R. Treatment paradigms in periodontal disease. Compend Contin Educ Dent 18 (1997) 221-232
52. Pichichero M.E., and Pichichero C.L. Persistent otitis media: causative pathogen. Pediatr Infect Dis J 14 (1995) 178-183
53. Leibovitz E., Raiz S., Piglansky L., et al. Resistance pattern of middle ear fluid isolates in acute otitis media recently treated with antibiotics. Pediatr Infect Dis J 17 (1998) 463-469
54. Casey J.R., and Pichichero M.E. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 23 (2004) 824-828
55. Heikkinen T., Thint M., and Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 340 (1999) 260-264
56. Brook I., Anthony B.V., and Finegold S.M. Aerobic and anaerobic bacteriology of acute otitis media in children. J Pediatr 92 (1978) 13-15
57. Brook I., Yocum P., Shah K., et al. The aerobic and anaerobic bacteriology of serous otitis media. Am J Otolaryngol 4 (1983) 389-392
58. Brook I., and Frazier E.H. Microbial dynamics of persistent purulent otitis media in children. J Pediatr 128 (1996) 237-240
59. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics 113 (2004) 1451-1465
60. Brook I. Prevalence of beta-lactamase-producing bacteria in chronic suppurative otitis media. Am J Dis Child 139 (1985) 280-284
61. Clinical practice guidelines: management of sinusitis. Pediatrics 108 (2001) 798-807
62. Niv A., Nash M., Peiser J., et al. Outpatient management of acute mastoiditis with periosteitis in children. International Journal of Pediatric Otorhinolaryngology 46 (1998) 9-13
63. Brook I. Aerobic and anaerobic bacteriology of chronic mastoiditis in children. Am J Dis Child 135 (1981) 478-479
64. Gwaltney Jr. J.M., Scheld W.M., Sande M.A., et al. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 90 (1992) 457-462
65. Wald E.R., Milmore G.J., Bowen A.D., et al. Acute maxillary sinusitis in children. N Engl J Med 304 (1981) 749-754
66. Brook I., Foote P.A., and Hausfeld J.N. Frequency of recovery of pathogens causing acute maxillary sinusitis in adults before and after introduction of vaccination of children with the 7-valent pneumococcal vaccine. J Med Microbiol 55 (2006) 943-946
67. Nord C.E. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. Clin Infect Dis 20 (1995) 1512-1524
68. Brook I. Microbiology of acute and chronic maxillary sinusitis associated with an odontogenic origin. Laryngoscope 115 (2005) 823-825
69. Decker C.F. Sinusitis in the immunocompromised host. Curr Infect Dis Rep 1 (1999) 27-32
70. Brook I. Management of chronic suppurative otitis media: superiority of therapy effective against anaerobic bacteria. Pediatr Infect Dis J 13 (1994) 188-193
71. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head and Neck Surg 130 Suppl 1 (2004) 1S-45S
72. Gordts F., Halewyck S., Pierard D., et al. Microbiology of the middle meatus: a comparison between normal adults and children. J Laryngol Otol 14 (2000) 184-188
73. Brook I. Bacteriology of acute and chronic ethmoid sinusitis. J Clin Microbiol 43 (2005) 3479-3480
74. Brook I. Bacteriology of acute and chronic frontal sinusitis. Arch Otolaryngol Head Neck Surg 128 (2002) 583-585
75. Brook I., Foote P.A., and Frazier E.H. Microbiology of acute exacerbation of chronic sinusitis. Ann Otol Rhinol Laryngol 114 (2005) 573-576
76. Brook I., Frazier E.H., and Foote P.A. Microbiology of the transition from acute to chronic maxillary sinusitis. J Med Microbiol 45 (1996) 372-375
77. Brook I. The role of anaerobic bacteria in tonsillitis. Int J Pediatr Otorhinolaryngol 69 (2005) 9-19
78. Brook I. Aerobic and anaerobic microbiology of peritonsillar abscess in children. Acta Paediatr Scand 70 (1981) 831-835
79. Brook I. Aerobic and anaerobic bacteriology of cervical adenitis in children. Clin Pediatr 19 (1980) 693-696
80. Brook I., and Yocum P. Comparison of the microbiology of group A streptococcal and non-group A streptococcal tonsillitis. Ann Otol Rhinol Laryngol 97 (1988) 243-246
81. Brook I., and Gober A.E. Treatment of non-streptococcal tonsillitis with metronidazole. Int J Pediatr Otorhinolaryngol 69 (2005) 65-68
82. Brook I., Foote Jr. P.A., Slots J., et al. Immune response to Prevotella intermedia in patients with recurrent non-streptococcal tonsillitis. Ann Otol Rhinol Laryngol 102 (1993) 113-116
83. Brook I., Foote P.A., and Slots J. Immune response to Fusobacterium nucleatum and Prevotella intermedia in patients with peritonsillar cellulitis and abscess. Clin Infect Dis 20 (1995) S220-S221
84. Kaplan E.L., and Johnson D.R. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group A streptococci from children with acute pharyngitis. Pediatrics 108 (2001) 1180-1186
85. Brook I. The role of bacterial interference in otitis, sinusitis and tonsillitis. Otolaryngol Head Neck Surg 133 (2005) 139-146
86. Brook I., and Gober A.E. Increased recovery of Moraxella catarrhalis and Haemophilus influenzae in association with group A beta-haemolytic streptococci in healthy children and those with pharyngo-tonsillitis. J Med Microbiol 55 (2006) 989-992
87. Bisno A.L., Gerber M.A., Gwaltney Jr. J.M., et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Disease Scoeity of America. Clin Infect Dis 35 (2002) 113-125
88. Colakoglu S., Alacam R., and Hascelik G. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Ankara, Turkey. Scand J Infect Dis 38 (2006) 456-459
89. Richter S.S., Heilmann K.P., Beekmann S.E., et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 41 (2005) 599-608
90. Casey J.R., and Pichichero M.E. Meta-analysis of cephalosporins versus penicillin for treatment of group A strepharyngo-tonsillitisococcal tonsillopharyngitis in adults. Clin Infect Dis 38 (2004) 1526-1534
91. Brook I. Antibacterial therapy for acute group a streptococcal pharyngotonsillitis: short-course versus traditional 10-day oral regimens. Paediatr Drugs 4 (2002) 747-754
92. Khayr W., and Taepke J. Management of peritonsillar abscess: needle aspiration versus incision and drainage versus tonsillectomy. Am J Ther 12 (2005) 344-350
93. Brook I. Microbiology of abscesses of the head and neck in children. Ann Otol Rhinol Laryngol 96 (1987) 429-433
94. Asmar B.I. Bacteriology of retropharyngeal abscess in children. Pediatr Infect Dis J 9 (1990) 595-596
95. Hughes C.E., Spear R.K., Shinabarger C.E., et al. Septic pulmonary emboli complicating mastoiditis: Lemierre's syndrome. Clin Infect Dis 18 (1994) 633-635
96. Brook I. Aerobic and anaerobic microbiology of suppurative sialadenitis. J Med Microbiol 51 (2002) 526-529
97. Brook I. Acute bacterial suppurative parotitis: microbiology and management. J Craniofac Surg 14 (2003) 37-40
98. Shah S.S., and Baum S.B. Infectious thyroiditis: diagnosis and management. Curr Infect Dis Rep 2 (2000) 147-153
99. Jeng L.B., Lin J.D., and Chen M.F. Acute suppurative thyroiditis: a ten year review in a Taiwanese hospital. Scand J Infect Dis 26 (1994) 297-300
100. Peters T.R., and Edwards K.M. Cervical lymphadenopathy and adenitis. Pediatr Rev 21 (2000) 399-405
101. Brook I., and Frazier E.H. Microbiology of cervical lymphadenitis in adults. Acta Otolaryngol 118 (1998) 443-446
102. Hazra R., Robson C.D., Perez-Atayde A.R., et al. Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Clin Infect Dis 28 (1999) 123-129
103. Brook I. Microbiology of infected epidermal cysts. Arch Dermatol 125 (1989) 1658-1661
104. Lemierre A. On certain septicemias due to anaerobic organisms. Lancet 2 (1936) 701-703
105. Brook I., and Hirokawa R. Post surgical wound infection after head and neck cancer surgery. Ann Otol Rhinol Laryngol 98 (1989) 322-325
106. Fraioli R., and Johnson J.T. Prevention and treatment of postsurgical head and neck infections. Curr Infect Dis Rep 6 (2004) 172-180